MX2014013525A - Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla. - Google Patents

Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla.

Info

Publication number
MX2014013525A
MX2014013525A MX2014013525A MX2014013525A MX2014013525A MX 2014013525 A MX2014013525 A MX 2014013525A MX 2014013525 A MX2014013525 A MX 2014013525A MX 2014013525 A MX2014013525 A MX 2014013525A MX 2014013525 A MX2014013525 A MX 2014013525A
Authority
MX
Mexico
Prior art keywords
salt
dimethylaminoethoxy
fumagillol
cinnarnoyl
making
Prior art date
Application number
MX2014013525A
Other languages
English (en)
Spanish (es)
Inventor
Thomas CRAWFORD
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of MX2014013525A publication Critical patent/MX2014013525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2014013525A 2012-05-07 2013-05-07 Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla. MX2014013525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643586P 2012-05-07 2012-05-07
PCT/US2013/039877 WO2013169727A1 (en) 2012-05-07 2013-05-07 Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2014013525A true MX2014013525A (es) 2015-10-22

Family

ID=48446683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013525A MX2014013525A (es) 2012-05-07 2013-05-07 Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla.

Country Status (10)

Country Link
US (1) US9260419B2 (OSRAM)
EP (1) EP2847176A1 (OSRAM)
JP (1) JP2015516425A (OSRAM)
KR (1) KR20150016303A (OSRAM)
AU (1) AU2013259760A1 (OSRAM)
BR (1) BR112014027808A2 (OSRAM)
CA (1) CA2872649A1 (OSRAM)
IL (1) IL235521A (OSRAM)
MX (1) MX2014013525A (OSRAM)
WO (1) WO2013169727A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
DE68927904T2 (de) 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
ATE87623T1 (de) 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (OSRAM) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE205092T1 (de) 1992-01-30 2001-09-15 Takeda Chemical Industries Ltd Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
DE69311278T2 (de) 1992-12-16 1997-10-30 Takeda Chemical Industries Ltd Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
DK0817626T3 (da) 1995-03-27 1999-07-12 Assist Publ Hopitaux De Paris Anvendelse af fumagillol og derivater deraf til fremstilling af lægemidler mod tarminfektioner
US6180626B1 (en) 1995-10-11 2001-01-30 Fujisawa Pharmaceutical Co., Ltd. Vascular-permeability suppressants
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
WO1998056372A1 (en) 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AU2002239479B2 (en) 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
WO2005066197A2 (en) 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006080591A1 (en) 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
NZ585547A (en) 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
WO2010065879A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form

Also Published As

Publication number Publication date
US20150111964A1 (en) 2015-04-23
BR112014027808A2 (pt) 2017-06-27
IL235521A (en) 2017-02-28
IL235521A0 (en) 2015-02-01
AU2013259760A1 (en) 2014-11-20
CN104350046A (zh) 2015-02-11
WO2013169727A1 (en) 2013-11-14
US9260419B2 (en) 2016-02-16
CA2872649A1 (en) 2013-11-14
EP2847176A1 (en) 2015-03-18
JP2015516425A (ja) 2015-06-11
KR20150016303A (ko) 2015-02-11

Similar Documents

Publication Publication Date Title
MX2014013525A (es) Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla.
IL244791A0 (en) Methods for modifying a host cell
ZA201507006B (en) Compositions and methods of nucleic acid-targeting nucleic acids
EP3079683A4 (en) Methods to treat lymphoplasmacytic lymphoma
EP2971040A4 (en) CELL CULTURE METHODS
EP2971014A4 (en) CELL CULTURE METHODS
EP3967747C0 (en) MICROORGANISMS AND PROCESSES FOR IMPROVING THE YIELDS OF METHANOL PRODUCTS USING ACETYL-COA SYNTHESIS
EP3079682A4 (en) Methods to treat lymphoplasmacytic lymphoma
SG11201609798XA (en) Real-time depth of field effects with design software
PT2983695T (pt) Métodos, usos e composições dos agonistas do tie2
GB2511212B (en) Over the air GNSS testing using multi-channel generators to create spatially-dispersed signals
GB201507664D0 (en) Composition & methods of screening
GB201319531D0 (en) Composition & methods of screening
HUE060769T2 (hu) Javított eljárás nagy koncentrációjú, vastartalmú oldat kinyerésére
ZA201506440B (en) Halogenopyrazoles as inhibitors of thrombin
PT3010896T (pt) Derivados inovadores de amidino-ureia macrocíclicos, métodos de preparação e utilizações dos mesmos como inibidores de quitinase
EP3003325A4 (en) Methods of evaluating cell culture additives
EP2962090A4 (en) MINIATURE NMR ANALYZER OF DRILLING ORIFICES AND METHODS OF USE
EP3046576A4 (en) Compositions and methods related to oat sensitivity
EP2825662A4 (en) ENZYMATIC REMOVAL OF STERYL GLYCOSIDES
IL244896A0 (en) History of indole-urea-converted glucopyranosyls and their use as sglt inhibitors
GB201312311D0 (en) Uses of enzyme inhibitors
GB2515256B (en) Structural Beam and Kit of Connectors Therefor
ES2390324B8 (es) Juego de brocas
SG2013060108A (en) Fluorescent-labeled artemisinin derivatives as bioimaging probes